Closed · RFA-CA-10-007 · CFDA 93.395 · Discretionary

Cancer Immunotherapy Trials Network (U01)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

Varies
Award range
Closed
Status
February 19, 2010
Close date
-
Expected awards

The verdict

Cancer Immunotherapy Trials Network (U01) is a closed discretionary listing from National Institutes of Health that offered Varies by applicant. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

Varies
award range
Closed
application status
93.395
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Cancer Immunotherapy Trials Network (U01) is closed (last close February 19, 2010). The parent program page for CFDA 93.395 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed February 19, 2010

Posted Dec 1 Closes Feb 19

Instrument

Cooperative Agreement

Description

Purpose. The purpose of this funding opportunity announcement (FOA) is to stimulate the conduct of early (Phase I and Phase II) clinical trials in the area of cancer immunotherapy by forming a Cancer Immunotherapy Trials Network (CITN). The emphasis is on clinical trials of high priority agents that were identified at the 2007 NCI immunotherapy agent workshop and on clinical trials using combinations of immunotherapy modalities and other agents. The CITN will support a multi-investigator team assembled to bring new immunotherapy agents to the clinic. This support will be realized through a single award for a Central Operations and Statistical Center (COSC) of the CITN. Whereas this FOA solicits applications specifically for the CITN COSC, the awardee team and their Program Directors/Principal Investigators (PDs/PIs) will provide overall leadership and statistical and protocol coordinator support for the CITN program. COSC applicants must plan that the CITN will include the following additional elements : (1) up to 25 institutions that will conduct the clinical trials as CITN Member Sites (supported through subcontracts within the COSC award); (2) support for tumor immunology laboratories that are associated with the Member Sites to conduct standardized immunomonitoring assays and biomarker and correlative studies related to the clinical trials; and (3) a data coordinating service that will be provided by a unit operated by the NCI (which remains beyond the scope of solicited applications).

Campus–civic applicant bridge · 4 doors

Cancer Immunotherapy Trials Network (U01) bridges educational institutions with civic applicant types (4 doors: Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); Private institutions of higher education). Expect campus and public/nonprofit operators in the same printed set. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 15 other National Institutes of Health listings share this exact eligibility-code string (0% of 12,420).

Code 06
Public / state-controlled institutions of higher education
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Cancer Immunotherapy Trials Network (U01) is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.395 may publish future NOFOs under the same assistance listing. Open program
  • Cancer Treatment Research indexes 60 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants